Welcome to the July 2024 issue of the Insife Newsletter. Through this newsletter we aim to keep you informed about news and developments from Insife and our partners.
Ingelise Bærentzen Melchiorsen, Head of Drug Safety at NNIT to speak at our Annual Insife Convention!
We kindly invite you to join us once again for our annual convention at the
Novartis Campus in Basel, Switzerland. Connect with industry leaders and enhance your expertise in pharmacovigilance, regulatory affairs, biotech, and clinical safety. Be part of a vibrant community where you can connect, collaborate, and grow together. Don't miss this opportunity!
revolutionized Pharmacovigilance, expanding globally with 8 offices and 130+ experts. Our innovative solutions, HALOPV & GRIP, streamline PV processes for diverse clients. Emphasizing shared values and sustainability, we cater to major pharma companies and regulatory agencies. As we celebrate our 7th anniversary, we remain committed to excellence and future advancements.
viewpoints on PV by our domain experts. Read the article about our Business
Development Director, Malin Kreitz and how she sees pharmacovigilance industry evolving rapidly, with technology playing a crucial role in advancing drug safety and
FDA Launches User Acceptance Testing for ESG NextGen
Modernization
The FDA will modernize the electronic submission gateway (ESG) by implementing an improved cloud-based modernization architecture that leverages an enterprise Identity and Access Management solution and that supports greatly expanding data submission bandwidth and storage, while continuing to ensure its stable operation.
